Takeda Files Routine 6-K Foreign Issuer Report

TL;DR

**Takeda filed a routine 6-K, nothing new to see here.**

AI Summary

Takeda Pharmaceutical Co Ltd filed a 6-K report on March 26, 2026, indicating a routine foreign issuer report. This filing, with accession number 0001395064-26-000102, provides no specific new financial or operational details beyond its existence. For investors, this particular 6-K filing is a standard procedural update and does not contain information that would immediately impact stock valuation or investment decisions.

Why It Matters

This filing is a standard procedural update for foreign companies listed in the U.S. and does not contain new material information that would typically affect the stock price.

Risk Assessment

Risk Level: low — This 6-K filing is purely administrative and does not disclose any new risks or material changes to the company's operations or financials.

Analyst Insight

Investors should note this is a routine administrative filing and does not contain new material information that would warrant immediate action. Continue to monitor for substantive filings.

Key Players & Entities

• TAKEDA PHARMACEUTICAL CO LTD (company) — the filer of the 6-K report
• 0001395064 (company) — the CIK of Takeda Pharmaceutical Co Ltd
• 2026-03-26 (date) — the filing date and period of report

FAQ

Filing Documents

• form6k_032626.htm (6-K) — 62KB
• 0001395064-26-000102.txt ( ) — 63KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date March 26, 2026 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller News Release Takeda Announces Candidates for Board of Directors and Change in Representative Director at Upcoming Shareholders Meeting OSAKA, Japan and CAMBRIDGE, Massachusetts, March 26, 2026 - Takeda (TSE4502NYSETAK) announced its Board of Directors decided today to propose candidates for internal and independent external directors at the 150th Ordinary General Meeting of Shareholders to be held on June 24, 2026. As the next step in the Company's previously announced 1 leadership transition, CEO-elect Julie Kim is proposed as a new candidate for the Board of Directors at the upcoming Ordinary General Meeting of Shareholders. If elected, the Board plans to appoint Ms. Kim as representative director, president CEO immediately following the meeting. Current Representative Director, President CEO Christophe Weber plans to retire from Takeda and its Board of Directors on the same day. 2 The new external candidates, Bruce Broussard, Koichiro Kimura and Paul Stoffels, will join the Board on June 24, if approved by shareholders. Current external directors Jean Luc Butel, Ian Clark, Yoshiaki Fujimori, Koji Hatsukawa, Emiko Higashi and Michel Orsinger will retire from the Board. All other current Board members will be proposed for re-election. "On behalf of Takeda's Board of Directors, I would like to express my sincere appreciation to our six retiring external board members for their dedicated service and invaluable contributions to Takeda over the last decade. Together with Christophe Weber, their leadership has been instrumental in driving Takeda's transformation," said Masami Iijima, chair of the Board of Directors

Forward-Looking Statements

Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could", "anticipates", "estimates", "projects", "forecasts", "outlook" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations competitive pressures and developments changes to applicable laws and regulations, including drug pricing, tax, tariff and other trade-related rules challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof uncertainty of commercial success for new and existing products manufacturing difficulties or delays fluctuations in interest and currency exchange rates claims or concerns regarding the safety or efficacy of marketed products or product candidates the impact of health crises, like the novel coronavirus pandemic the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our b

View Full Filing

View this 6-K filing on SEC EDGAR